Reduced Claudin-12 Expression Predicts Poor Prognosis in Cervical Cancer.

ABSTRACT:

Background

Within the claudin (CLDN) family, CLDN12 mRNA expression is altered in various types of cancer, but its clinicopathological relevance has yet to be established due to the absence of specific antibodies (Abs) with broad applications.

Methods

We generated a monoclonal Ab (mAb) against human/mouse CLDN12 and verified its specificity. By performing immunohistochemical staining and semiquantification, we evaluated the relationship between CLDN12 expression and clinicopathological parameters in tissues from 138 cases of cervical cancer.

Results

Western blot and immunohistochemical analyses revealed that the established mAb selectively recognized the CLDN12 protein. Twenty six of the 138 cases (18.8%) showed low CLDN12 expression, and the disease-specific s

SUBMITTER: Rahman A 

PROVIDER: S-EPMC8038723 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature